Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Loser

Onyx Pharmaceuticals ( ONXX) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.6%. By the end of trading, Onyx Pharmaceuticals fell 54 cents (-0.8%) to $67.76 on light volume. Throughout the day, 1.1 million shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of two million shares. The stock ranged in price between $67.41-$68.52 after having opened the day at $68 as compared to the previous trading day's close of $68.30. Other company's within the Drugs industry that declined today were: Natural Alternatives International ( NAII), down 18.4%, StemCells ( STEM), down 17.2%, Anthera Pharmaceuticals ( ANTH), down 16.9%, and MEI Pharma ( MEIP), down 12.8%.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $4.25 billion and is part of the health care sector. The company has a P/E ratio of 60, below the average drugs industry P/E ratio of 60.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 50.3% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share.

On the positive front, Somaxon Pharmaceuticals ( SOMX), up 61.5%, Supernus Pharmaceuticals ( SUPN), up 37%, ADVENTRX Pharmaceuticals ( ANX), up 19.1%, and Cormedix ( CRMD), up 17.3%, were all gainers within the drugs industry with GlaxoSmithKline ( GSK) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon

U.S. Crude Oil Hits Fresh 3-Year Highs as Gasoline Heads to $3 a Gallon